Janet Jin's Biography

Janet Jin, Director of Assay Development, Roche Sequencing Solutions

Dr. Janet Jin, PhD is a cancer biologist and product development scientist, currently serving as the director of assay development at Roche Sequencing Solutions. Dr. Jin’s team is responsible for developing Next Generation Sequencing based oncology products, as well as conducting a number of clinical research collaborations with internal and external partners to apply NGS-based oncology assays in clinical research settings. Dr. Jin began her professional career in discovery oncology at Roche/Genentech, identifying novel targets for the small molecule drug discovery program. She subsequently joined the Genomics and Oncology research team at Roche Molecular Systems, where she led the effort to develop NGS based oncology assays to support internal IVD development projects. Dr. Jin received her PhD in Cancer Biology from Stanford University, School of Medicine. She received her Bachelor degree from the University of California, Berkeley, in Molecular and Cell Biology, with an emphasis in Genetics.

Monitoring Disease Burden and Resistance to Targeted Therapy in Solid Tumors Using Liquid Biopsies

Thursday, 5 October 2017 at 09:30

Add to Calendar ▼2017-10-05 09:30:002017-10-05 10:30:00Europe/LondonMonitoring Disease Burden and Resistance to Targeted Therapy in Solid Tumors Using Liquid BiopsiesLiquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

The potential of liquid biopsies for use in clinical research and patient management in oncology is of significant interest to clinicians as a complementary tool to tumor tissue testing. Next Generation Sequencing (NGS) technologies enable testing of multiple markers in one assay, overcoming the challenges of limited sample availability. Potential applications of NGS-based circulating tumor DNA (ctDNA) analysis include high-risk screening, surveillance, treatment prediction and monitoring for disease recurrence/resistance. Comprehensive testing of disease burden from ctDNA in plasma is currently used for clinical research. The AVENIO ctDNA Analysis Kits (For Research Use Only) offer researchers the option to sequence predictive markers, as well as highly mutated regions to assess disease burden and identifying resistance to targeted therapies in solid tumors. Our research demonstrates the potential utility for testing ctDNA to identify an increased risk of disease progression in colorectal cancer; and to identify resistance mechanisms to targeted therapy in lung cancer. Further clinical validation is required.

Add to Calendar ▼2017-10-05 00:00:002017-10-06 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2017Liquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors